

## Press Information

June 24, 2010

### **TET Systems and SIRION BIOTECH GmbH sign a commercial license agreement**

München/Martinsried, TET Systems (TET) and SIRION BIOTECH GmbH, two privately-held, German biotech companies based in Heidelberg and Martinsried near Munich, respectively, announced today that they have signed a commercial license agreement. Under the terms of the agreement, SIRION BIOTECH offers customized services to its clients using the Tet Technology to generate cell lines and to generate and manufacture recombinant viral vector products.

“We are very pleased to sign this commercial license agreement with SIRION BIOTECH. The services offered by SIRION BIOTECH, in particular the recombinant adenoviral production services, have not been available through our existing Authorized Partner Network and SIRION BIOTECH’S addition nicely complements our existing network. Since there has been demand in the past for these services from our existing licensees and academic institutions we expect that this new agreement will be the basis for a successful business relationship with SIRION BIOTECH,” stated Dr. Ernst Boehnlein, CEO of TET Systems. “We will continue to add to our Partner Network to fill existing gaps, to accommodate our customers` demands and to make new technologies available to our licensees.”

The license of the Tet Technology allows SIRION BIOTECH to switch on or turn off the induced gene products in genetically modified cells. The use of this technology expands the services of the company and helps to circumvent the disadvantages of traditional genetically modified cells with permanent gene expression. The Tet Technology leads to a broader application range of SIRION BIOTECH vectors. Hence Pharma and Biotech customers are able to achieve better results in screening and providing higher success rates in target validation.

“With the licensing of the Tet Technology we are broadening our customer`s benefits fundamentally and therefore have added a substantial revenue driver to the services we already offer,” said Dr. Christian Thirion, CSO of SIRION BIOTECH.

#### **About TET Systems**

TET Systems is a privately held company located in Heidelberg, Germany. TET Systems was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems owns a broad patent portfolio covering the technology organized in six patent families comprising 35 granted patents and 15 patent applications. To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research



foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.

### **About SIRION BIOTECH**

SIRION BIOTECH GmbH is a biotech company that produces genetically modified cells and is a technology provider in the area of viral vector systems. The company founded in 2006 is located in the Innovations- und Gründerzentrum Biotechnologie IZB in Martinsried near Munich. The expert in RNAi technology offers a wide range of more than 100 products and services. Using state-of-the art techniques and assay systems the company offers reliable lead-through service projects in target validation, screening and drug discovery.

With its strong expertise in cell line development SIRION BIOTECH serves as a partner for the development and optimization of cell lines for various applications like the production of vaccine or antibodies or the built up of cellular assay systems.

SIRION BIOTECH currently operates projects for most of the major pharmaceutical companies in Europe and USA and has ongoing collaborations with leading academic and governmental research institutes.

### **Contact:**

#### **TET Systems GmbH & Co. KG**

Dr. Ernst Böhnlein  
Chief Executive Officer  
Phone: +49 (6221) 588 0400  
boehnlein@tet-systems.com

#### **SIRION BIOTECH GmbH**

Holger Schmidt  
PR Manager  
Phone: +49 (0) 8106-37 97 171  
Fax: +49(0)8106-37 97 171,  
E-Mail: holgerachim.schmidt@web.de  
www.sirion-biotech.de